{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gp100%3A209-217+%28210M%29", "query": { "intervention": "gp100:209-217 (210M)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gp100%3A209-217+%28210M%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T19:55:25.247Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00020475", "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extraocular Extension Melanoma", "Recurrent Intraocular Melanoma" ], "interventions": [ { "name": "gp100 antigen", "type": "DRUG" }, { "name": "interleukin-2", "type": "DRUG" }, { "name": "MART-1 antigen", "type": "DRUG" }, { "name": "Montanide ISA-51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": null, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-10-05T19:55:25.247Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020475" }, { "nct_id": "NCT00059475", "title": "Peptide Vaccination for Patients at High Risk for Recurrent Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Glycoprotein 100 (GP100): 209-217 (210M)", "type": "DRUG" }, { "name": "Interleukin-2 (IL-2)", "type": "DRUG" }, { "name": "Montanide ISA 51", "type": "DRUG" }, { "name": "Melanoma antigen recognized by T-cells (MART)-1: 27-35", "type": "DRUG" }, { "name": "27-35 (27L): melanoma antigen recognized by T-cells (MART)-1", "type": "DRUG" }, { "name": "melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 138, "start_date": "2003-04", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2012-10-23", "last_synced_at": "2026-10-05T19:55:25.247Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00059475" }, { "nct_id": "NCT00798629", "title": "Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "Autologous dendritic cell-adenovirus CCL21 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2008-11", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2012-09-24", "last_synced_at": "2026-10-05T19:55:25.247Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00798629" }, { "nct_id": "NCT00001832", "title": "Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Neoplasm Metastasis" ], "interventions": [ { "name": "gp100:209-217 (210M)", "type": "DRUG" }, { "name": "Montanide ISA-51", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "MART-1:26-35(27L)", "type": "DRUG" }, { "name": "Abl cells", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GCSF (Growth colony stimulating factor)", "type": "BIOLOGICAL" }, { "name": "Apheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 170, "start_date": "1999-08", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2012-12-21", "last_synced_at": "2026-10-05T19:55:25.247Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001832" }, { "nct_id": "NCT00580060", "title": "Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20, "start_date": "2003-12", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2011-06-10", "last_synced_at": "2026-10-05T19:55:25.247Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580060" }, { "nct_id": "NCT00313508", "title": "Dendritic Cell Vaccination During Lymphoid Reconstruction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "Autologous Dendritic Cells (DC)", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Autologous Lymphocyte Infusion (ALI)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 18, "start_date": "2006-02", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2014-02-21", "last_synced_at": "2026-10-05T19:55:25.247Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00313508" }, { "nct_id": "NCT01989559", "title": "Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Melanoma", "Stage IA Skin Melanoma", "Stage IB Skin Melanoma", "Stage IIA Skin Melanoma", "Stage IIB Skin Melanoma", "Stage IIC Skin Melanoma", "Stage IIIA Skin Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "gp100:209-217(210M) Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "HPV 16 E7:12-20 Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "2002-10", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2015-01-26", "last_synced_at": "2026-10-05T19:55:25.247Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01989559" }, { "nct_id": "NCT01176461", "title": "Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "MART-1", "type": "BIOLOGICAL" }, { "name": "NY-ESO-1", "type": "BIOLOGICAL" }, { "name": "gp100:209-217(210M)", "type": "BIOLOGICAL" }, { "name": "gp100:280-288(288V)", "type": "BIOLOGICAL" }, { "name": "Montanide ISA 51 VG", "type": "DRUG" }, { "name": "BMS-936558", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 127, "start_date": "2010-08-04", "completion_date": "2016-12-12", "has_results": false, "last_update_posted_date": "2023-01-18", "last_synced_at": "2026-10-05T19:55:25.247Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01176461" }, { "nct_id": "NCT00003895", "title": "Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IA Melanoma", "Stage IB Melanoma", "Stage IIA Melanoma", "Stage IIB Melanoma", "Stage IIC Melanoma", "Stage IIIA Melanoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma" ], "interventions": [ { "name": "HPV 16 E7:12-20", "type": "BIOLOGICAL" }, { "name": "gp100:209-217(210M)", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 36, "start_date": "1999-04", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2017-02-20", "last_synced_at": "2026-10-05T19:55:25.247Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003895" }, { "nct_id": "NCT00303836", "title": "Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2005-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-06", "last_synced_at": "2026-10-05T19:55:25.247Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00303836" } ] }